Answers are grounded in this paper and cite their sources.
Only limited therapeutic agents have been developed for non-alcoholic steatohepatitis (NASH). Glabridin, a promising anti-obesity candidate, has only limited druggability due to its low in vivo chemical stability and bioavailability. Therefore, we developed vutiglabridin (VUTI), which is based on a glabridin backbone, and investigated its mechanism of action in treating NASH in animal models.
No takes yet. Share an insight, caveat, or question.
Shin et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: